ASRT: חוב כולל להון Assertio Therapeutics

Assertio Holdings, Inc. (ASRT) is currently reviewing its neurological drug portfolio and restructuring internal processes following the consolidation of assets to return to profitability. Large loans and competition from affordable generics are undermining the company's financial stability. The market capitalization trend based on the total debt-to-equity ratio is fixed at 0.51, while the company is implementing wastewater treatment systems and the safe disposal of chemical waste.

Assertio Holdings, Inc. (ASRT) is minimizing its reliance on individual patents and stabilizing cash flows through the diversification of its neurological drug portfolio and the development of digital sales channels. By analyzing the total liabilities-to-equity ratio, investors assess the balance between debt and equity, where an increase in this metric signals rising credit risk and a decline in the issuer's financial autonomy.